Ignite Creation Date:
2024-05-05 @ 4:42 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00294372
Status:
TERMINATED
Last Update Posted:
2013-11-14
First Post:
2006-02-20
Brief Title:
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected NNRTI-treated Patients
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
Randomised Double-blind Placebo-controlled 7 Day Monotherapy Phase IIa Study to Evaluate the Antiviral Activity and Safety of Increasing Doses of Oral Administered RTV-boosted BILR 355 BS 75 mg and 150 mg Twice Daily in HIV-1-infected NNRTI-experienced Patients Followed by 28 Day Combination Therapy With Tipranavir or Lopinavir Based HAART-regimen
Status:
TERMINATED
Status Verified Date:
2013-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The general aim is to evaluate the antiviral activity and safety of increasing doses of oral administered RTV-boosted BILR 355 BS 75 mg and 150 mg twice daily in HIV-1-infected NNRTI-experienced patients followed by 28 day combination therapy with Tipranavir or Lopinavir based HAART-regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None